Effects of statin therapy and treatment duration on cardiovascular disease risk in patients with nephrotic syndrome: A nested case–control study. Issue 4 (3rd March 2022)

• Record Type: Journal Article
• Authors: Zou, Xinliang; Nie, Li; Liao, Yi; Liu, Zhihui; Zheng, Wanxiang; Qu, Xiaolong; Xu, Xiang; Qin, Haoran; Wang, Haidong; Liu, Jianping; He, Guoxiang; Jing, Tao
• Is Part Of: Pharmacotherapy. Volume 42:Issue 4(2022)
• Page Start: 311
• Page End: 319
• Publication Date: 2022-03-03
• Subjects: cardiovascular disease -- lipid disorders -- nephrotic syndrome -- statin treatment; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2675
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract: Background: Although statins are the cornerstone of lipid management, hardly any of the existing studies on statin treatment of dyslipidemia in nephrotic syndrome (NS) addressed patient‐centered outcomes of cardiovascular events. Objective: To evaluate whether statin treatment impacts the outcomes of cardiovascular events in patients with NS. Design: A single‐center, retrospective, nested case–control study analyzed data from the First Affiliated Hospital of Army Medical University. Patients: Patients diagnosed with NS from January 1, 1999, to November 30, 2014, were selected and followed up for 5 years. Measurements and Main Results: A total of 2706 patients with NS were enrolled in this study cohort. Among these, 115 patients diagnosed with cardiovascular disease (CVD) at the end of the observational period and 235 CVD‐free controls enrolled by 1:2 matching with gender, age, and index time were included in the study. Propensity score matching was used to match (1:1) the baseline characteristics of the cases and controls. The chi‐square test was performed based on whether the patient used a statin as an exposure factor, and binary logistic regression analysis of the association between cardiovascular events and statin therapy duration was conducted. Subgroup analyses for relevant variables were also performed. The chi‐square test showed that statin therapy was significantly associated with a reduction in CVD risk in patients with NS ( p = 0.002). Furthermore, the risk of cardiovascular events in patients with NS decreased as the length of statin treatment increased (OR = 0.82 [95% CI 0.73–0.89], p < 0.001). Conclusions: For NS patients with dyslipidemia, statin therapy may be used to decrease CVD risk, and extended treatment was associated with more significant risk reduction.